Anebulo Pharmaceuticals Inc (ANEB)
Official siteBIOTECHNOLOGY
Last updated: Nov 13, 2026 at 4:00 PM ET
Anebulo Pharmaceuticals Inc (ANEB) Financials: Revenue, Profit and Cash Flow
Anebulo Pharmaceuticals reported revenue of $0 for the fiscal year ended Jun 30, 2025. That year, net income was -$8.48M, operating cash flow was -$6.35M and free cash flow was -$6.35M. The quarter ended Dec 31, 2025 had revenue of $0 and net income of -$2.00M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Jun 2025, with an operating loss of $9.22M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | $0 | N/A | N/A | N/A | N/A |
| Jun 2024 | $0 | N/A | N/A | N/A | N/A |
| Jun 2023 | $0 | N/A | N/A | N/A | N/A |
| Jun 2022 | $0 | N/A | N/A | N/A | N/A |
| Jun 2021 | $0 | N/A | N/A | N/A | N/A |
| Jun 2020 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Jun 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
| Research and development | $4.30M | $3.55M | $5.60M | $2.96M | $2.27M | $150.00K |
| Operating income | -$9.22M | -$8.31M | -$11.78M | -$6.83M | -$3.61M | -$173.35K |
| Net income | -$8.48M | -$8.20M | -$11.73M | -$6.83M | -$30.25M | -$174.64K |
| EBITDA | -$7.98M | -$8.15M | N/A | N/A | N/A | -$173.35K |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.62M | -$2.26M | -$2.33M | -$1.89M | -$2.59M | -$2.41M | -$1.34M | -$1.66M | -$2.76M | -$2.54M | -$2.49M | -$2.86M |
| Net income | -$2.00M | -$2.16M | -$2.14M | -$1.68M | -$2.46M | -$2.20M | -$1.35M | -$1.65M | -$2.72M | -$2.48M | -$2.50M | -$2.80M |
Balance Sheet
As of Jun 2025, cash and equivalents of $11.63M were 95.7% of total assets of $12.15M, against total liabilities of $487.69K.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $12.15M | $4.07M | $11.67M | $15.58M | $21.65M | $3.03M | $3.03M |
| Current assets | $11.96M | $3.51M | $11.67M | $15.58M | $21.65M | $3.03M | $3.03M |
| Cash and equivalents | $11.63M | $3.09M | $11.25M | $14.55M | $19.99M | $3.02M | $3.02M |
| Total liabilities | $487.69K | $260.58K | $1.07M | $512.53K | $241.63K | $223.87K | $223.87K |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | $201.29K | $201.29K |
| Shareholder equity | $11.66M | $3.81M | $10.60M | $15.07M | $21.41M | -$171.14K | -$171.14K |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $9.42M | $10.70M | $12.15M | $14.01M | $15.84M | $2.47M | $4.07M | $6.00M | $7.50M | $9.05M | $11.67M | $14.43M |
| Total liabilities | $1.49M | $963.82K | $487.69K | $546.03K | $878.80K | $569.23K | $260.58K | $1.01M | $1.01M | $716.56K | $1.07M | $1.49M |
| Cash and equivalents | $9.04M | $10.35M | $11.63M | $13.28M | $15.00M | $1.40M | $3.09M | $5.15M | $6.64M | $8.52M | $11.25M | $14.16M |
| Shareholder equity | $7.94M | $9.74M | $11.66M | $13.46M | $14.96M | $1.90M | $3.81M | $4.99M | $6.49M | $8.33M | $10.60M | $12.94M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2025.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.35M | -$8.09M | -$9.68M | -$5.44M | -$4.87M | -$150.77K |
| Capital expenditures | $3 | $1 | $0 | $4 | $0 | $2 |
| Free cash flow | -$6.35M | -$8.09M | -$9.68M | -$5.44M | -$4.87M | -$150.77K |
| Dividends paid | N/A | N/A | N/A | N/A | $8.21M | N/A |
| Share repurchases | N/A | N/A | $317.08K | $0 | N/A | N/A |
| Financing cash flow | $14.88M | -$62.35K | $6.38M | $0 | $21.83M | $3.18M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.31M | -$1.27M | -$1.65M | -$1.60M | -$1.41M | -$1.69M | -$2.05M | -$1.50M | -$1.81M | -$2.73M | -$2.85M | -$2.19M |
| Capital expenditures | $0 | $0 | $0 | $0 | $4 | $0 | $1 | $0 | $3 | $5 | $4 | $0 |
| Free cash flow | -$1.31M | -$1.27M | -$1.65M | -$1.60M | -$1.41M | -$1.69M | -$2.05M | -$1.50M | -$1.81M | -$2.73M | -$2.85M | -$2.19M |
Frequently Asked Questions About ANEB
What is Anebulo Pharmaceuticals' annual revenue?
Anebulo Pharmaceuticals reported revenue of $0 for the fiscal year ended Jun 30, 2025.
Is Anebulo Pharmaceuticals profitable?
No. Anebulo Pharmaceuticals reported net income of -$8.48M for the fiscal year ended Jun 30, 2025.
How much free cash flow does ANEB generate?
For the fiscal year ended Jun 30, 2025, operating cash flow of -$6.35M minus capital expenditures of $3 produced free cash flow of -$6.35M.
How much debt does Anebulo Pharmaceuticals have?
The balance sheet dated Jun 30, 2025 reported cash and equivalents of $11.63M.
ANEB pages: Overview, Financials